Milestone Scientific Inc.(MLSS)Earnings, Financials & Key RatiosMilestone Scientific Inc. (MLSS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve operating leverage, combined with a rapidly depleting cash balance of $1.2 million against quarterly operating losses, presents an unsustainable risk profile for long-term investors.
Milestone Scientific Inc. (MLSS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Milestone Scientific Inc. (MLSS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.01vs $0.01+33.3% | $2Mvs $2M-4.0% |
| Q2 2026 | Mar 31, 2026 | $0.02vs $0.01-33.3% | $2Mvs $2M-10.6% |
| Q4 2025 | Nov 13, 2025 | $0.01vs $0.01+33.3% | $2Mvs $2M+2.2% |
| Q3 2025 | Aug 14, 2025 | $0.02vs $0.01-100.0% | $2Mvs $2M+1.0% |
Recent stock market news and headlines for Milestone Scientific Inc. (MLSS)
ROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a series of strategic governance initiatives designed to support the Company's continued evolution and long-term growth.
Key metrics vs top competitors for Milestone Scientific Inc. (MLSS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.32 | $28.16M | -4.57 | 3.99% | -63.76% | -132.38% | — | |
| $11.01 | $2.21B | -3.67 | -2.98% | -17.06% | -41.19% | — | |
| $84.95 | $9.68B | 25.98 | 4.03% | 2.95% | 8.14% | — | |
| $26.96 | $4.39B | 96.29 | 8.32% | 2.41% | 2.18% | — | |
| $178.43 | $12.78B | 31.58 | 0.9% | 10.5% | 10.7% | — | |
| $42.98 | $614.51M | -52.41 | -4.91% | -14.59% | -15.59% | — |
Milestone Scientific Inc. (MLSS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Milestone Scientific Inc. (MLSS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
May 6, 2026·SEC
Apr 21, 2026·SEC
Get notified when MLSS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Milestone Scientific Inc. (MLSS) stock FAQ — growth, dividends, profitability & financials explained
Milestone Scientific Inc. (MLSS) reported $8.9M in revenue for fiscal year 2025. This represents a 2868% increase from $0.3M in 1996.
Milestone Scientific Inc. (MLSS) grew revenue by 4.0% over the past year. Growth has been modest.
Milestone Scientific Inc. (MLSS) reported a net loss of $4.6M for fiscal year 2025.
Milestone Scientific Inc. (MLSS) has a return on equity (ROE) of -132.4%. Negative ROE indicates the company is unprofitable.
Milestone Scientific Inc. (MLSS) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.
